Ignite Creation Date:
2024-05-06 @ 12:00 AM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01461044
Status:
COMPLETED
Last Update Posted:
2016-01-26
First Post:
2011-10-24
Brief Title:
An Observational Study of Avastin Bevacizumab in Patients With HER2-metastatic or Locally Advanced Breast Cancer
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Ambispective Non Interventional Study of 2 Cohorts Triple Negative or HR of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin Bevacizumab 1st Line for at Least 12 Months and Without Progression for at Least 12 Months
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This observational study will evaluate the safety and efficacy of triple negative or HR patients with HER2-metastatic or locally advanced breast cancer treated with Avastin bevacizumab as first line therapy for at least 12 months and without disease progression for at least 12 months Data will be collected retrospectively from the diagnosis to the inclusion in the study and for 18 months from study start
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None